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ABSTRACT 
Objective: Although recent advances in the treatment of congestive heart disease, mortality among patients’ remains a questionable remark. 
Therefore, we evaluated the role of capsaicin on in vitro and ex vivo platelet aggregation induced by Adenosine Di-Phosphate (ADP) as well as in in 
vivo thrombosis models and role of NO, KATP was also identified in the capsaicin-induced anti-platelet animal model as well as in vivo model of 
arterial thrombosis. 
Methods: According to body weight wistar rats were divided into five groups. Group I and Group II was treated with saline and capsaicin (3 mg/kg, 
i. v), while animals from Group III were treated with N(ω)-nitro-L-arginine methyl ester (L-NAME) (30 mg/kg, i. v) 30 min before administration of 
capsaicin (3 mg/kg, i. v). Group IV animals were treated with glibenclamide (10 mg/kg,i. v) 30 min before administration of capsaicin (3 mg/kg, i. v). 
Group V was considered as a positive control and administered clopidogrel (30 mg/kg, p. o). Animals were subjected for in vitro, ex-vivo platelet 
aggregation assay. ADP (30µM) was utilized as an aggregating agent in these experiments. After these assays; animals of each group were subjected 
for subaqueous tail bleeding time in a rat model and FeCl3-induced arterial thrombosis model in rats. 
Results: In ADP-induced in vitro platelet aggregation, a significant reduction in % platelet aggregation was observed at 50µM (64.35±4.641) and 
100µM (52.72±4.192) concentration of capsaicin as compared to vehicle control (85.82±3.716). Capsaicin (3 mg/kg, i. v) also showed a significant 
reduction (49.53±4.075) in ex-vivo ADP-induced platelet aggregation as compared to vehicle control (89.38±2.057). In FeCl3 induced arterial 
thrombosis model, Capsaicin (3 mg/kg, i. v) exhibited an increase in time to occlusion in this rodent model and presence of the L-NAME and 
glibenclamide had inhibited the activity of capsaicin.  
Conclusion: In our study, capsaicin (50 µM, 100µM) exhibited potent anti-platelet activity in ADP-induced platelet aggregation, similarly capsaicin 
exhibited significant anti-platelet action in the ex-vivo study. Moreover, the presence of L-NAME and glibenclamide inhibited the anti-thrombotic 
and anti-platelet action of capsaicin. Therefore, it was concluded that NO and KATP may be involved in the anti-thrombotic action of capsaicin. 
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Heart attacks and strokes are the most common causes of mortality 
and morbidity across the world and both represent clinical 
manifestations of acute arterial thrombosis [1]. Among them, 
atherosclerosis presents a greater risk to cardiovascular and 
peripheral vascular system causing mortality in cardiovascular 
disease patients [2]. Thrombus formation is a key mediator in the 
development of atherosclerosis [3]. The platelet is believed to play a 
pivotal role in pathogenesis and progression of atherosclerosis [4]. 
Previously it was believed that the platelet is having a minor role in 
this process; however, it is recognized that the platelet places itself 
as a critical link between thrombus formation, inflammation, and 
atherosclerosis [5]. At the site of vascular injury, platelets come into 
contact with subendothelial components and form a plug-like 
structure to avoid future damage to the endothelium. However, if the 
injury continues to happen, it will activate the cascade of signalling 
molecules which will form thrombus at the site of injury. This will 
lead to life-threatening disease states such as myocardial infarction, 
atherosclerosis or ischemic stroke [6]. 
Upon platelet formation at the site of vascular injury a series of 
cascade initiates which mainly involves three phases. Phase I, Phase 
II and Phase III name as the initial phase, extension phase and 
stabilization phase respectively. The initial phase involves 
attachment of platelets to the exposed sub-endothelial layer 
following vascular injury and a monolayer of activated cells is 
formed. This activated monolayer further recruits more additional 
platelets to construct another strong layer during extension phase 
[7]. In order to restrict the recently formed thrombus to the initial 
injury site, regulation of platelet aggregation is the process to 
modulate a balance between activation and inhibition of signalling 
pathway of platelet [8]. Any defect in regulation of platelet activation 
or aggregation can cause arterial thrombosis, the major 
manifestation of atherosclerosis which triggers myocardial 
infarction and stroke. Nitric oxide (NO) is an endogenous gas 
present in endothelial cell of vascular endothelium, which is 
believed to play a predominant role in the regulation of platelet 
aggregation [9]. Endothelial NO responsible for maintenance of basal 
vascular tone and blood flow, and thereby regulation of blood 
pressure due to vasodilatory action [10].  
A substantial amount of research has been carried out to elucidate 
the role of NO in platelet aggregation and found that NO can inhibit 
platelet activation or aggregation in vitro and in vivo [11]. The 
mechanism by which inhibition of platelet aggregation turns out by 
NO is caused by the cGMP-dependent pathway. Soluble 
guanylcyclase (sGC) is an enzyme responsible for the production of 
cyclic guanosine monophosphate (cGMP), and NO is involved in 
activation of sGC which further lead to activation of cGMP-
dependent protein kinase (PKG) via a cGMP-dependent pathway. 
This activated PKG caused inhibition of platelet activation via 
phosphorylating TxTA2 receptors and thus inhibits its aggregating 
action on platelet. Further details include inhibition of influx of 
Ca2+and other positive ions via activating sarcoplasmic reticulum 
ATPase (SERCA) [12]. PKG is also involved in blockage of the release 
of Ca2+ cation from the sarcoplasmic reticulum via inhibition of 
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inositol-1,4,5-trisphosphate, which also contributes to the lower 
level of intracellular cytosolic Ca2+[13,14]. Other than above-
mentioned mechanisms, two other mechanisms have been identified 
for platelet aggregation prevention caused by cGMP. It has been 
identified that cGMP inhibits phosphodiesterase type III enzyme and 
thereby causing elevation of the intracellular cAMP level; cGMP and 
cAMP act synergistically to inhibit platelet aggregation [15]. In 
another study, it has been identified that inhibition of PI3K activation 
by cGMP leads to activation of GP IIb-IIIa fibrinogen receptors [16]. 
Various cascades of pathways are being targeted in medical 
therapies to develop anti-platelet agents. These include therapies 
aimed at inhibiting TxA2, ADP, GPIIb/IIIa, thrombin, collagen. 
Although major therapeutics is available in the area of thrombosis, 
disease prevalence is a cause of concern for healthcare industries in 
the world. Hence, we aimed to identify the role of capsaicin in 
platelet aggregation and mechanism of it. Capsaicin is a pungent 
photochemical present in peppers responsible for spiciness [17]. 
Capsaicin is a potent agonist of TRPV1 channel distributed 
throughout the body. TRPV1 channel plays a very important role in 
heat sensation [18]. Nitric oxide (NO) plays a pivotal role in pain 
sensation via activation of TRPV1 channel [19].  
A number of few reports suggest that capsaicin have potential to 
inhibit platelet activation. Capsaicin was found to inhibit the 
aggregating effects of collagen in mouse platelet [20]. However, a 
significant amount of data spars regarding the detailed mechanism 
of action of capsaicin in platelet inhibitory action. To our best of 
knowledge, it has not been studied the role of capsaicin with respect 
to NO in platelet aggregation. Therefore, current investigation aimed 
to identify the role of capsaicin in platelet aggregation and elucidate 
the role of NO, KATP in capsaicin mediated anti-platelet activity. 
MATERIALS AND METHODS 
Animals 
Albino Wistar rats (150–200 g) were housed in a climate-controlled 
room (temperature 22±1 °C; relative humidity 55%±5%) on a 12 h 
(light)–12 h (dark) cycle. Animals had access to a standard pellet 
diet (Certified Amrut brand rodent feed; Pranav Agro Industries, 
Pune, India) and filtered tap water ad libitum. All experiments were 
carried out with strict adherence to ethical guidelines and were 
conducted according to the protocol (LMCP/Cology/14/10) 
approved by the Institutional Animal Ethics Committee (IAEC), and 
according to Indian norms set by the Committee for the Purpose of 
Control and Supervision of Experiments on Animals (CPCSEA, New 
Delhi, India). In addition, the animals were cared for in accordance 
with the Guide to the Care and Use of Experimental Animals (Vol. 1, 
2nd ed., 1993, and Vol. 2, 1984) throughout the study. Throughout 
the entire study period, the animals were monitored for growth and 
health status to be certain that they were healthy. 
Chemicals 
Capsaicin, ADP (Adenosine Diphosphate) and Urethane were also 
purchased from Sigma Chemical, USA and ADP were prepared in 
phosphate buffer (pH 7.4). FeCl3 was purchased from Hi-Media, 
India. Clopidogrel bisulfate was the generous gift from Zydus Cadila, 
India. In all experiments, water for injection was utilized for 
preparation of L-NAME and clopidogrel whereas capsaicin, 
glibenclamide was prepared in DMSO (0.5%)+saline.  
Preparation of platelet-rich plasma (PRP) and platelet poor 
plasma (PPP) 
Blood was collected into the tubes containing 3.8% trisodium citrate 
via retro-orbital route under light ether anesthesia from rats. All blood 
samples were centrifuged at 200Xg for 20 min and supernatant patelet 
rich plasma (PRP) was collected carefully. The remaining amount of 
blood was centrifuged at 800Xg for 20 min and supernatant platelet 
poor plasma (PPP) was collected with utmost care.  
Measurement of platelet aggregation using ADP as an 
aggregating agent 
Platelet aggregation studies were performed on microplate reader in 
96-well, flat-bottomed, microtiter plates. A 180-μl volume of PRP 
was placed in each well, followed by addition of 20 μl of ADP 
(30µM). For in vitro studies, PRP/PPP was incubated with various 
concentrations of capsaicin (25, 50 and 100 μM) for 2 min at 37 °C 
before addition of ADP. Readings were taken every 1-min over a 5-
min period at 405-nm wavelength. During the runtime, the plate was 
incubated at 37 °C and was shaken vigorously in a shaking mode at 
the maximal speed available. All platelet aggregation studies were 
performed in triplicate. Change in optical density (OD) was 
measured by taking OD of buffer as blank.  
% Aggregation was calculated using formula:  
% Aggregation = [(Initial OD-Final OD)/Initial OD]*100 
Experimental design for ex vivo platelet aggregation study in rats 
On the basis of body weight wistar rats were randomly divided into 
following groups. Experimental design was given in fig. 1. 
 
 
Fig. 1: Experimental design for ex vivo platelet aggregation study 
 
Via the retro-orbital route blood samples were collected in tubes 
containing 3.8% trisodium citrate under anesthesia. PRP/PPP was 
prepared as described above and samples were subjected to ADP-
induced platelet aggregation assay. % Aggregation was calculated 
in order to estimate the influence of capsaicin in platelet 
aggregation. 
Subaqueous tail bleeding time in rat 
Anaesthetized rats were fixed in supine position on a temperature-
controlled (37 °C) heating table. After a defined latency period, the 
tail of the rat was transected with a razor-blade mounted on a self-
constructed device at a distance of 4 mm from the tip of the tail. 
Immediately after transection, the tail was immersed into a bath 
filled with isotonic saline solution (37 °C). The time until continuous 
blood flow ceased for >30 s was measured, with a maximum 
observation time of 30 min (longer bleeding times were assigned a 
value of 30 min). Clopidogrel (30 mg/kg, p. o., 120 min pretreatment 
time) was used as positive control. 
FeCl3-induced arterial thrombosis model in rats 
Rats (n=6) were treated as per given protocol and then subjected to 
FeCl3-induced arterial thrombosis. The fecl3-induced chemical injury 
was used as a model of arterial thrombosis. A midline cervical 
incision was made on the ventral side of the neck and left carotid 
artery was isolated. Cannulation of the carotid artery was performed 
and connected to blood pressure measurement instrument (Biopac 
Systems, Inc, California, USA for B. P. measurement). A2×3 mm strip 
of Whatman filter paper No. #1 saturated with 35% (w/v) FeCl3 was 
kept on the carotid artery for 5 min. A sudden decrease in B. P. 
signalling was taken as an indicator of cessation of blood flow as a 
consequence to thrombus formation. Time to occlusion (TTO) was 
defined as the time from FeCl3 application to time of thrombus 
formation. A cutoff time was fixed at 60 min in case no thrombus 
formation was seen in drug-treated animals. Assessments of wet 
thrombus weight were also performed. 
Statistical analysis 
Results were expressed as mean±SEM. Data were analyzed by One-
way ANOVA followed by Dunnet’s multiple comparison tests. All 
analysis was performed using graphpad prism software® version 
6.0. P<0.05 was considered to be statistically significant. 
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RESULTS 
Effects of capsaicin on ADP-induced in vitro and ex vivo platelet 
aggregation and mechanisms 
In ADP-induced in vitro platelet aggregation, capsaicin exhibited a 
significant reduction in % platelet aggregation at 50µM 
(64.35±4.641) and 100µM (52.72±4.192) concentration as 
compared to vehicle control (85.82±3.716) (fig. 2). On another hand, 
capsaicin (3 mg/kg, i. v) also showed a significant reduction 
(49.53±4.075) in ex-vivo ADP-induced platelet aggregation as 
compared to vehicle control (89.38±2.057) (fig. 3). We also explored 
the mechanism of antiplatelet action of capsaicin by using L-NAME 
and glibenclamide to identify the role of NO and KATP in capsaicin 
mediated antiplatelet action. Capsaicin at 3 mg/kg, i. v exhibited a 
significant reduction in % platelet aggregation (49.53±4.075) as 
compared to vehicle control (89.38±2.057) (fig. 3). Pretreatment of 
L-NAME somehow inhibited platelet inhibitory action of capsaicin, 
while on other hand addition of glibenclamide exhibited inhibition 









































Fig. 2: Effects of capsaicin on ADP-induced platelet aggregation 
in vitro, NRM-normal control group, CPS-capsaicin treated 




























Fig. 3: Effects of capsaicin on ADP-induced platelet aggregation 
ex-vivo, NRM-normal control group, CPS= capsaicin-treated 
group (3 mg/kg), L-N+CPS=30 mg/kg L-NAME with 3 mg/kg 
Capsaicin, G+CPS=Glibenclamide 10 mg/kg with 3 mg/kg 
Capsaicin treated group, CLP=Clopidogrel 30 mg/kg treated 
group served as positive control; #=p<0.01 vs NRM, @=p<0.05 vs 
NRM 
 
Effects of capsaicin in vivo models of subaqueous tail bleeding time 
and FeCl3 induced thrombosis in rats and mechanisms involved 
Following ex-vivo and in vitro platelet aggregation assay we carried 
out in vivo model of thrombosis to explore the role of capsaicin in 
thrombosis and its underlying mechanism. Capsaicin (3 mg/kg, i. v.) 
(446.3±38.75) showed a significant rise in bleeding time as 
compared to vehicle control (241.8±17.94). Further, bleeding time 
for capsaicin (3 mg/kg, i. v.) is significantly lower than positive 
control clopidogrel (30 mg/kg, p. o.) (fig. 4). Bleeding time is a 
significant parameter of antiplatelet or anticoagulant activity; 
therefore it has a major impact on the identification of antiplatelet or 
anticoagulant effect of the substance. In our study, pretreatment of 
L-NAME significantly blocked the antiplatelet effect of capsaicin, 
while on another hand a significant rise in bleeding time was 
observed with the addition of glibenclamide to capsaicin as 
compared to vehicle control (fig. 4). However, bleeding time for 
glibenclamide pretreated group was significantly lower than 
positive control. Hence, it can be concluded that NO may be involved 


























Fig. 4: Effects of capsaicin on bleeding time (Seconds). 
Inhibitors were used 30 min prior to capsaicin administration. 
NRM-Normal Control Group, CPS= Capsaicin treated Group (3 
mg/kg), L-N+CPS=30 mg/kg L-NAME with 3 mg/kg Capsaicin, 
G+CPS=Glibenclamide 10 mg/kg with 3 mg/kg Capsaicin 
treated group, CLP=Clopidogrel 30 mg/kg treated group served 
as positive control; #=p<0.01 vs NRM, @=p<0.05 vs NRM 
 
Moreover, FeCl3 induced arterial thrombosis model was also performed 
to elucidate the role and mechanism of capsaicin in platelet aggregation. 
In that, time to occlusion (TTO) was measured as endpoint parameter. 
Capsaicin (3 mg/kg, i. v.) exhibited an increase in time to occlusion in this 
rodent model as shown in fig. below (fig. 5). This action was completely 
reversed in presence of L-NAME, while the presence of glibenclamide 
partially inhibited the activity of capsaicin as compared to vehicle 
control. Reduction in thrombus weight was observed in capsaicin-
treated group whereas L-NAME and glibenclamide exhibited inhibition 



























Fig. 5: Effects of capsaicin on time to carotid artery occlusion (TTO) 
using FeCl3-induced arterial thrombosis in male wistar rats. 
Inhibitors were used 30 min prior to capsaicin administration. 
NRM-normal control group, CPS= capsaicin-treated group (3 
mg/kg), L-N+CPS=30 mg/kg L-NAME with 3 mg/kg Capsaicin, 
G+CPS=Glibenclamide 10 mg/kg with 3 mg/kg Capsaicin treated 
group, CLP=Clopidogrel 30 mg/kg treated group served as positive 
control; #=p<0.01 vs NRM, @=p<0.05 vs NRM 
























Fig. 6: Effects of capsaicin on thrombus wet weight FeCl3-
induced thrombosis model in rats. NRM-normal control group, 
CPS= capsaicin-treated group (3 mg/kg), L-N+CPS=30 mg/kg L-
NAME with 3 mg/kg Capsaicin, G+CPS=Glibenclamide 10 mg/kg 
with 30 mg/kg Capsaicin treated group, CLP=Clopidogrel 30 
mg/kg treated group served as positive control; #=p<0.01 vs 
NRM, @=p<0.05 vs NRM 
 
DISCUSSION 
Antiplatelet activity of capsaicin has been studied in many 
literatures; however, mechanism of its action remains a 
controversial. Here, we tried to identify the role of various signaling 
molecules in antiplatelet activity of capsaicin. It is well-known fact 
that NO plays an important role in modulation of platelet activity. 
Now days, platelet aggregation is a prime topic of discussion because 
of dependency of leading cardiovascular diseases such as myocardial 
infarction and atherosclerosis on platelet modulation. Transient 
receptor potential vanilloid receptor 1 (TRPV1), has established its 
pivotal role in the modulation of pain and inflammatory responses in 
neurons via in multiple chemical and physical stimuli [21]. It is well 
known fact that capsaicin serves as a potent agonist of TRPV1 and 
activates these channels [22]. The activation of TRPV1 channels 
results in increased [Ca2+]i level and thereby downstream of 
signaling cascades activation takes place. Besides its pivotal role in 
pain modulation, the TRPV1 channels are also found to be playing a 
major role in regulating the physiological functions of cardiovascular 
cells and the pathogenesis of cardiovascular diseases [23]. In spite of 
progress in research of capsaicin and cardiovascular research in last 
decade, the role and effects of capsaicin on platelet aggregation are 
not studied well. Several reports states that activation of TRPV1 
channels in endothelial cells protects against atherosclerosis, 
hypertension and stroke via activation of NO [24]. However, role of 
NO is not elucidated well in platelet function. Hence, we correlated 
capsaicin with TRPV1 to determine the role of NO using platelet 
aggregation assay and arterial model of thrombosis.  
There are limited reports available suggesting antithrombotic effects 
of capsaicin and direct role of capsaicin in in vivo thrombosis model 
has not been studied well. Therefore, we investigated the role of 
capsaicin in antiplatelet activity and evaluated its mechanism(s). We 
identified that capsaicin exhibited significant anti-platelet effect at 
100µM concentration as compared to vehicle control in in vitro 
platelet aggregation study. Moreover, we investigated the role of NO 
and KATP by using L-NAME and glibenclamide, respectively in ex vivo 
and in vivo model of thrombosis. It was observed that capsaicin (3 
mg/kg, i. v.) significantly reduced platelet aggregation in in vitro and 
ex-vivo study and pretreatment of L-NAME and glibenclamide 
partially blocked anti-platelet effect of capsaicin in similar models 
suggests NO and KATP may have a role in the anti-platelet effect of 
capsaicin. Going further, we investigated the role of capsaicin in an 
arterial model of thrombosis and found that capsaicin significantly 
increased the time to occlude in FeCl3 induced thrombus formation 
model as compared to vehicle control and interestingly, 
pretreatment of L-NAME and KATP blocked the antithrombotic action 
of capsaicin in the same model. Above observations suggest that 
capsaicin may have antithrombotic activity via NO-cGMP pathway. A 
drug characteristic belongs to antiplatelet or anticoagulant can be 
identified on the basis of bleeding profile of the drug, hence we 
studied the bleeding profile of capsaicin using tail vein bleeding time 
rodent model. We observed that bleeding time for the capsaicin-
treated group was significantly decreased as compared to vehicle 
control but much more than positive control (clopidogrel). 
Therefore, it can be concluded that capsaicin has a little effect on 
blood coagulation but not significant. It has been demonstrated that 
thrombus composition is an indicator of coronary occlusion time. 
“Fresh” thrombi have the highest portion of platelets, while the 
proportion of fibrin fibers increases over time, as the level of 
thrombin increases, leading to “older” fibrin-rich thrombi [25]. In 
our study, thrombus formed by FeCl3 was less than within a day 
hence it is to be considered as fresh thrombus composed of high 
portion of platelet and it is also documented in previous studies. In a 
model of FeCl3 induced thrombus, capsaicin has significantly showed 
inhibitory action on thrombus formation. Therefore, it can be 
concluded that capsaicin may exert antithrombotic effect by 
inhibiting structural platelet inhibition via induction of NO from 
endothelium. In our result, effect of fibrin was not observed due to 
thrombin structure was confined to rich level of platelet than fibrin 
clot. Hence, our study supports the previous finding of antiplatelet 
activity of capsaicin [26]. Eguchi et al. demonstrated that endothelial 
cell mitochondria have decisive role on thrombus formation process. 
Upon injury to endothelium, reactive oxygen species (ROS) enhance 
the process of thrombus formation which is attenuated by KATP channel 
opener [27]. In our study of FeCl3 induced thrombosis; thrombus was 
formed as a result of damage to the endothelium was caused by FeCl3. 
This thrombus formation time and its extent were attenuated by the 
treatment of capsaicin. However, addition of glibenclamide to 
capsaicin somehow shifted the antithrombotic activity of capsaicin 
towards KATP channel which was not significant. Our results are not 
consistent with observation of Mittelstadt who stated that Capsaicin-
induced inhibition of platelet aggregation is not mediated by TRPV1 
[28]. In our experiments results, partial involvement of KATP was seen 
in various parameters of arterial model of thrombosis hence the role 
of KATP channel in capsaicin offered antithrombotic action could not be 
neglected. Therefore, it would not be wrong to say that activation of 
TRPV1 channel by capsaicin may have opened KATP in the endothelium 
of artery of rat.  
CONCLUSION 
In conclusion, our current investigation also supports previous finding 
showing capsaicin’s role in platelet aggregation, moreover, we have 
also investigated the mechanism of antiplatelet activity of capsaicin. 
We have found that NO plays a predominant role in the anti-platelet 
action of capsaicin via activation of sGC-cGMP modulatory signalling 
pathway and shift of anti-thrombotic activity towards KATP channel 
was also evident from our current investigation result. This may be 
due to activation of TRV1 by capsaicin. One previous report stated anti-
platelet activity of capsaicin is unrelated to TRPV1, while in our 
investigation it has been showed that role of TRPV1 in thrombosis of 
artery via KATP cannot be neglected.  
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